BIOGEN INC. Finite-Lived Intangible Assets, Accumulated Amortization
BIOGEN INC. (BIIB) had Finite-Lived Intangible Assets, Accumulated Amortization of $6.82 billion as of 2026-03-31, per its 10-Q filed 2026-04-29.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent › Intangible Asset, Excluding Goodwill, after Accumulated Amortization › Intangible Asset, Finite-Lived, after Accumulated Amortization
us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization · last filed 2026-04-29
- 2026-03-31: Finite-Lived Intangible Assets, Accumulated Amortization $6.82B.
- 2025-12-31: Finite-Lived Intangible Assets, Accumulated Amortization $6.69B.
- 2025-09-30: Finite-Lived Intangible Assets, Accumulated Amortization $6.56B.
- 2025-06-30: Finite-Lived Intangible Assets, Accumulated Amortization $6.42B.
| Period end | Finite-Lived Intangible Assets, Accumulated Amortization | Finite-Lived Intangible Assets, Accumulated Amortization as first filed |
|---|---|---|
| 2026-03-31 | $6.82B 10-Q · filed 2026-04-29 | |
| 2025-12-31 | $6.69B 10-Q · filed 2026-04-29 | |
| 2025-09-30 | $6.56B 10-Q · filed 2025-10-30 | |
| 2025-06-30 | $6.42B 10-Q · filed 2025-07-31 | |
| 2025-03-31 | $6.33B 10-Q · filed 2025-05-01 | |
| 2024-12-31 | $6.25B 10-K · filed 2026-02-06 | |
| 2024-09-30 | $6.14B 10-Q · filed 2024-10-30 | |
| 2024-06-30 | $6.04B 10-Q · filed 2024-08-01 | |
| 2024-03-31 | $5.95B 10-Q · filed 2024-04-24 | |
| 2023-12-31 | $5.87B 10-K · filed 2025-02-12 | |
| 2023-09-30 | $5.79B 10-Q · filed 2023-11-08 | |
| 2023-06-30 | $5.73B 10-Q · filed 2023-07-25 | |
| 2023-03-31 | $5.68B 10-Q · filed 2023-04-25 | |
| 2022-12-31 | $5.63B 10-K · filed 2024-02-14 | |
| 2022-09-30 | $5.58B 10-Q · filed 2022-10-25 | |
| 2022-06-30 | $5.52B 10-Q · filed 2022-07-20 | |
| 2022-03-31 | $5.46B 10-Q · filed 2022-05-03 | |
| 2021-12-31 | $5.39B 10-K · filed 2023-02-15 | |
| 2021-09-30 | $5.32B 10-Q · filed 2021-10-20 | |
| 2021-06-30 | $5.25B 10-Q · filed 2021-07-22 | |
| 2021-03-31 | $5.19B 10-Q · filed 2021-04-22 | |
| 2020-12-31 | $5.14B 10-K · filed 2022-02-03 | |
| 2020-09-30 | $5.08B 10-Q · filed 2020-10-21 | |
| 2020-06-30 | $5.01B 10-Q · filed 2020-07-22 | |
| 2020-03-31 | $4.95B 10-Q · filed 2020-04-23 | |
| 2019-12-31 | $4.88B 10-K · filed 2021-02-03 | |
| 2019-09-30 | $4.81B 10-Q · filed 2019-10-22 | |
| 2019-06-30 | $4.75B 10-Q · filed 2019-07-24 | |
| 2019-03-31 | $4.68B 10-Q · filed 2019-04-24 | |
| 2018-12-31 | $4.61B 10-K · filed 2020-02-06 | |
| 2018-09-30 | $4.69B 10-Q · filed 2018-10-23 | |
| 2018-06-30 | $4.60B 10-Q · filed 2018-07-24 | |
| 2018-03-31 | $4.49B 10-Q · filed 2018-04-24 | |
| 2017-12-31 | $4.38B 10-K · filed 2019-02-06 | |
| 2017-09-30 | $4.28B 10-Q · filed 2017-10-24 | |
| 2017-06-30 | $4.17B 10-Q · filed 2017-07-25 | |
| 2017-03-31 | $4.05B 10-Q · filed 2017-04-25 | |
| 2016-12-31 | $3.93B 10-K · filed 2018-02-01 | |
| 2016-09-30 | $3.84B 10-Q · filed 2016-10-26 | |
| 2016-06-30 | $3.74B 10-Q · filed 2016-07-21 | |
| 2016-03-31 | $3.65B 10-Q · filed 2016-04-21 | |
| 2015-12-31 | $3.56B 10-K · filed 2017-02-02 | |
| 2015-09-30 | $3.46B 10-Q · filed 2015-10-21 | |
| 2015-06-30 | $3.37B 10-Q · filed 2015-07-24 | |
| 2015-03-31 | $3.27B 10-Q · filed 2015-04-24 | |
| 2014-12-31 | $3.18B 10-K · filed 2016-02-03 | |
| 2014-09-30 | $3.07B 10-Q · filed 2014-10-22 | |
| 2014-06-30 | $2.97B 10-Q · filed 2014-07-23 | |
| 2014-03-31 | $2.85B 10-Q · filed 2014-04-23 | |
| 2013-12-31 | $2.74B 10-K · filed 2015-02-04 | |
| 2013-09-30 | $2.63B 10-Q · filed 2013-10-28 | |
| 2013-06-30 | $2.53B 10-Q · filed 2013-07-25 | |
| 2013-03-31 | $2.45B 10-Q · filed 2013-04-25 | |
| 2012-12-31 | $2.40B 10-K · filed 2014-02-06 | $2.40B 10-K · filed 2013-02-05 |
| 2012-09-30 | $2.35B 10-Q · filed 2012-10-25 | |
| 2012-06-30 | $2.30B 10-Q · filed 2012-07-24 | |
| 2012-03-31 | $2.25B 10-Q · filed 2012-05-01 | |
| 2011-12-31 | $2.20B 10-K · filed 2013-02-05 | $2.21B 10-K · filed 2012-02-03 |
| 2011-09-30 | $2.16B 10-Q · filed 2011-10-28 | |
| 2011-06-30 | $2.11B 10-Q · filed 2011-07-26 | |
| 2010-12-31 | $2.00B 10-K · filed 2012-02-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |